Analysts expect Arcadia Biosciences Inc (NASDAQ:RKDA) to report earnings per share (EPS) of ($0.70) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Arcadia Biosciences’ earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.68). Arcadia Biosciences posted earnings of ($0.14) per share in the same quarter last year, which indicates a negative year over year growth rate of 400%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 25th.
According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($3.17) to ($3.15). For the next year, analysts expect that the business will post earnings of ($2.19) per share, with EPS estimates ranging from ($2.54) to ($1.84). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27). The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.
In other Arcadia Biosciences news, Director Kevin Comcowich acquired 5,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $5.88 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at $117,600. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 32,200 shares of company stock worth $188,076. Insiders own 3.30% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in Arcadia Biosciences in the second quarter worth $32,000. Cambridge Investment Research Advisors Inc. purchased a new position in Arcadia Biosciences in the second quarter worth $34,000. Squarepoint Ops LLC purchased a new position in Arcadia Biosciences in the third quarter worth $124,000. Sabby Management LLC boosted its position in Arcadia Biosciences by 150.0% in the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Arcadia Biosciences by 47.1% in the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after purchasing an additional 37,472 shares during the last quarter. 8.03% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ RKDA traded up $0.22 during midday trading on Wednesday, hitting $5.19. 3,833 shares of the stock traded hands, compared to its average volume of 685,477. The company has a market cap of $42.99 million, a PE ratio of -0.97 and a beta of -2.98. Arcadia Biosciences has a one year low of $1.82 and a one year high of $10.40. The business has a 50 day moving average price of $4.69 and a two-hundred day moving average price of $4.68. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.27 and a current ratio of 5.58.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Recommended Story: Stock Portfolio Tracker
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.